Hunan Fangsheng Pharmaceutical Co., Ltd. (SHA:603998)
China · Delayed Price · Currency is CNY 11.70
-0.05 (-0.43%)
Feb 4, 2026, 1:14 PM CST
SHA:603998 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,615 | 1,710 | 1,569 | 1,751 | 1,535 | 1,252 |
Other Revenue | 67.69 | 67.69 | 59.09 | 41.27 | 32.12 | 27.15 |
| 1,683 | 1,777 | 1,629 | 1,792 | 1,567 | 1,279 | |
Revenue Growth (YoY) | -4.47% | 9.15% | -9.12% | 14.36% | 22.54% | 16.91% |
Cost of Revenue | 511.12 | 517.01 | 522.25 | 589.28 | 566.27 | 468.18 |
Gross Profit | 1,172 | 1,260 | 1,106 | 1,203 | 1,001 | 810.58 |
Selling, General & Admin | 715.77 | 846.57 | 804.8 | 940.45 | 798.94 | 635.9 |
Research & Development | 143.91 | 139.21 | 107.93 | 70.4 | 51.4 | 53.62 |
Other Operating Expenses | 36.29 | 23.3 | 29.27 | 28.55 | 24.33 | 19.41 |
Operating Expenses | 884.54 | 1,013 | 942.99 | 1,049 | 877.34 | 718.63 |
Operating Income | 287.19 | 247.14 | 163.31 | 153.98 | 123.37 | 91.95 |
Interest Expense | -17.3 | -21.79 | -20.81 | -22.95 | -18.39 | -16.83 |
Interest & Investment Income | 1.38 | 48.22 | 10.64 | 171 | 1.77 | 3.59 |
Currency Exchange Gain (Loss) | - | - | - | 0.16 | -0.57 | - |
Other Non Operating Income (Expenses) | -2.35 | -1.25 | -2.22 | -15.14 | -2.46 | -2.64 |
EBT Excluding Unusual Items | 268.92 | 272.32 | 150.92 | 287.05 | 103.72 | 76.07 |
Impairment of Goodwill | -5.38 | -5.38 | - | - | - | -1.23 |
Gain (Loss) on Sale of Investments | -0.87 | -0.82 | -5.46 | -0.06 | -21.17 | -22.33 |
Gain (Loss) on Sale of Assets | 51.31 | 0.7 | 11.38 | -1.03 | -0.94 | -0.51 |
Asset Writedown | 2.02 | - | - | - | - | - |
Other Unusual Items | 19.17 | 19.17 | 46.5 | 40.63 | 9.18 | 16.97 |
Pretax Income | 335.17 | 285.99 | 203.34 | 326.57 | 90.79 | 68.97 |
Income Tax Expense | 47.37 | 36.14 | 23.71 | 49.87 | 20.87 | 15.2 |
Earnings From Continuing Operations | 287.8 | 249.85 | 179.62 | 276.71 | 69.92 | 53.78 |
Minority Interest in Earnings | 7.56 | 5.37 | 7.2 | 9.15 | 0.12 | 10.02 |
Net Income | 295.36 | 255.22 | 186.82 | 285.85 | 70.04 | 63.79 |
Net Income to Common | 295.36 | 255.22 | 186.82 | 285.85 | 70.04 | 63.79 |
Net Income Growth | 8.21% | 36.61% | -34.64% | 308.13% | 9.79% | -19.16% |
Shares Outstanding (Basic) | 440 | 433 | 434 | 433 | 438 | 425 |
Shares Outstanding (Diluted) | 441 | 440 | 445 | 433 | 438 | 425 |
Shares Change (YoY) | -2.28% | -1.08% | 2.70% | -1.06% | 2.93% | -2.99% |
EPS (Basic) | 0.67 | 0.59 | 0.43 | 0.66 | 0.16 | 0.15 |
EPS (Diluted) | 0.67 | 0.58 | 0.42 | 0.66 | 0.16 | 0.15 |
EPS Growth | 10.73% | 38.09% | -36.36% | 312.50% | 6.67% | -16.67% |
Free Cash Flow | 224 | 100.16 | -131.24 | 130.38 | 0.92 | 68.9 |
Free Cash Flow Per Share | 0.51 | 0.23 | -0.29 | 0.30 | 0.00 | 0.16 |
Dividend Per Share | 0.350 | 0.250 | 0.290 | 0.350 | 0.150 | 0.120 |
Dividend Growth | 40.00% | -13.79% | -17.14% | 133.33% | 25.00% | 100.00% |
Gross Margin | 69.63% | 70.91% | 67.93% | 67.12% | 63.86% | 63.39% |
Operating Margin | 17.07% | 13.90% | 10.03% | 8.59% | 7.87% | 7.19% |
Profit Margin | 17.55% | 14.36% | 11.47% | 15.95% | 4.47% | 4.99% |
Free Cash Flow Margin | 13.31% | 5.63% | -8.06% | 7.28% | 0.06% | 5.39% |
EBITDA | 361.28 | 320.22 | 235.04 | 223.65 | 190.74 | 162.4 |
EBITDA Margin | 21.47% | 18.02% | 14.43% | 12.48% | 12.17% | 12.70% |
D&A For EBITDA | 74.09 | 73.08 | 71.73 | 69.67 | 67.38 | 70.45 |
EBIT | 287.19 | 247.14 | 163.31 | 153.98 | 123.37 | 91.95 |
EBIT Margin | 17.07% | 13.90% | 10.03% | 8.59% | 7.87% | 7.19% |
Effective Tax Rate | 14.13% | 12.64% | 11.66% | 15.27% | 22.99% | 22.03% |
Revenue as Reported | 1,683 | 1,777 | 1,629 | 1,792 | 1,567 | 1,279 |
Advertising Expenses | - | 145.33 | 77.28 | 34.32 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.